Notre équipe chargée des secteurs Sciences de la Vie et Santé compte parmi ses clients des sociétés de l’industrie médicale (laboratoires pharmaceutiques et fabricants de dispositifs médicaux) parmi les plus importantes au monde, ainsi que de nombreuses petites et moyennes entreprises. Notre équipe permet aux clients de faire face aux nombreux défis juridiques et commerciaux qu’ils doivent relever dans ces secteurs dynamiques et hautement réglementés.
L’équipe Sciences de la Vie de Taylor Wessing, reconnue comme l’un des leaders du marché, est en mesure d’apporter un service juridique complet aux laboratoires pharmaceutiques, sociétés de biotechnologies, fabricants de dispositifs médicaux, sociétés de recherche et développement, et autres prestataires du secteur.
L’expertise de l’équipe porte sur l’ensemble des problématiques rencontrées par les sociétés du secteur et sur une connaissance de la réglementation européenne et nationale, et lui vaut une réputation sur le marché au niveau international.
Que votre société soit une start-up ou une multinationale, Taylor Wessing est en mesure de vous accompagner tout au long du cycle de vie de votre produit, depuis sa conception et son développement, jusqu’à sa défense face aux produits concurrents.
Le cadre législatif et réglementaire du secteur de la santé diffère grandement d’une juridiction à une autre. Ces différences requièrent des connaissances spécialisées aux plans national et international. Nos avocats présents auprès de l’ensemble des bureaux de Taylor Wessing, experts dans ces domaines pourront vous assister et vous accompagner dans vos projets transfrontaliers et internationaux.
Pour la plus grande satisfaction des clients, l’équipe est en mesure de vous accompagner sur l’ensemble des domaines suivants :
Domaines d’expertise
Bioteche-santéInvestisseurs et protection sociale Investisseurs et Start-ups en sciences de la vie Dispositifs médicauxProduits pharmaceutiquesWe have advised Blue Earth Therapeutics and its management on the closing of US$76.5 million Series A funding. The new funding comes from a broad spectrum of experienced biotech investors and enables Blue Earth Therapeutics to further advance its clinical stage prostate-specific membrane antigen-targeted radioligand therapies.
Press releaseWe have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.
Press releaseWe advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press releaseOberberg Group on the successful refinancing of its existing credit lines. The new financing also served several add-on acquisitions. This included the internationally renowned private clinic Jägerwinkel am Tegernsee, which is expanding the treatment spectrum of the Group with its range of integrative holistic psychosomatics with a focus on interdisciplinary pain therapy. In addition, Panorama Fachklinik, an acute hospital for psychosomatics, and Privatklinik Hubertus im Allgäu, a specialist hospital for psychosomatics, psychotherapy and naturopathy, were acquired.
Press releaseSteadfast Capital Fund IV on the acquisition of a majority stake in Söhngen Group. The transaction included both W. Söhngen GmbH based in Taunusstein (Hesse) and Silva GmbH based in Mainhausen (Hesse). The parties have agreed not to disclose the purchase price. The majority acquisition aims to support further growth of the Söhngen Group with its internationally recognised brands and premium products in the market for first aid and emergency medical products both organically and through acquisitions. We also advised on the financing of the acquisition.
Press releaseNORD Holding, a leading private equity house, on the acquisition of the majority interest in Zentrum Gesundheit Group, a leading German group of ophthalmic surgery and diagnostic centres, from Waterland Private Equity. NORD Holding, together with the management and medical team, acquired a stake as a new partner and majority shareholder. In this deal the Taylor Wessing team again demonstrated its interdisciplinary expertise in the areas of healthcare M&A, regulatory and acquisition financing.
Press releaseActualités et publications récentes
Open Source in Healthcare and Life Sciences – Legal Framework and Compliance Requirements
Open source in healthcare requires robust compliance and security standards.
par Jan Feuerhake, LL.M. (Melbourne) et Gabriel Danyeli, LL.M. (Köln/Istanbul Bilgi)
The UPC’s first referral to the European Court of Justice: Cross-border preliminary injunctions against intermediaries and non-UPC defendants
par plusieurs auteurs
Hungarian supreme court on legal standing to challenge generic marketing authorisations
Case law – Hungarian Supreme Court (Kúria), precedent-setting judgment of 7 May 2026 – Kfv.37.810/2025/27 – On legal standing to challenge generic marketing authorisations
par Fruzsina Kónya
8 de 9 Publications
Case law – VfGH on the eImpfpass and central vaccination register
The Austrian Constitutional Court rejected challenges to the eImpfpass and central vaccination register on procedural grounds. The decision leaves the register in place, but highlights the role of data protection remedies in digital health infrastructure.
6 de 9 Publications
The new Product Liability Directive: three life sciences priorities before the 2026 deadline
The new EU Product Liability Directive applies to products placed on the market after 9 December 2026. Three changes call for decisions by life sciences companies now: software and AI as products, an eased burden of proof, and disclosure of internal evidence.
par Bartosz Świdrak
3 de 9 Publications
Patent Map
An interactive tool providing guidance when planning your litigation strategy across Europe and the UPC.
MDR Medical Device Checker
Our MDR Medical Device Checker assesses the likelihood of your product falling within the scope of the Medical Devices Regulation.